Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
From the perspective of US payers, at a willingness-to-pay threshold of $150,000 per QALY, the combination of EV and pembrolizumab is estimated to not be cost-effective compared to traditional chemotherapy in the first-line treatment of mUC patients.
Authors
- Ouyang Xie
- Long Wang (ORCID: https://orcid.org/0000-0002-2274-177X)
- Heng Xiang
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-6007-4170)
- Andong Li (ORCID: https://orcid.org/0000-0001-5291-2720)
- Kehui Meng
- Meiyu Wu
- Xiaomin Wan
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.3389/fimmu.2024.1464092
- Citations
- 12
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.87
Funders
- Health Commission of Hunan Province
- National Natural Science Foundation of China
- Central South University
- Natural Science Foundation of Hunan Province
- Fundamental Research Funds for the Central Universities
- Fundamental Research Funds for Central Universities of the Central South University